51 related articles for article (PubMed ID: 11809699)
1. The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis.
Chang CS; Brossay L; Kronenberg M; Kane KP
J Exp Med; 1999 Feb; 189(3):483-91. PubMed ID: 9927510
[TBL] [Abstract][Full Text] [Related]
2. Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.
Tomita Y; Watanabe H; Kobayashi H; Nishiyama T; Tsuji S; Fujiwara M; Sato S
Cancer Immunol Immunother; 1992; 35(6):381-7. PubMed ID: 1356627
[TBL] [Abstract][Full Text] [Related]
3. Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro.
Takahashi T; Ishikura H; Iwai K; Takahashi C; Kato H; Tanabe T; Yoshiki T
Cancer Immunol Immunother; 1993; 36(2):76-82. PubMed ID: 8093857
[TBL] [Abstract][Full Text] [Related]
4. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
Correale P; Procopio A; Celio L; Caraglia M; Genua G; Coppola V; Pepe S; Normanno N; Vecchio I; Palmieri G
Cancer Immunol Immunother; 1992; 34(4):272-8. PubMed ID: 1371427
[TBL] [Abstract][Full Text] [Related]
5. Lysis of endothelial cells by autologous lymphokine-activated killer cells.
Kitayama J; Tsuno N; Yasuhara H; Nagawa H; Kimura W; Kuroda A; Shibata Y; Juji T; Muto T
Cancer Immunol Immunother; 1994 May; 38(5):317-22. PubMed ID: 8162614
[TBL] [Abstract][Full Text] [Related]
6. High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity.
Tanio Y; Watanabe M; Osaki T; Tachibana I; Kawase I; Kuritani T; Saito S; Masuno T; Kodama N; Furuse K
Jpn J Cancer Res; 1992 Jul; 83(7):736-45. PubMed ID: 1325431
[TBL] [Abstract][Full Text] [Related]
7. Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment.
Yanase M; Tsukamoto T; Kumamoto Y; Kato K; Hashimoto Y
Cancer Immunol Immunother; 1994 Jul; 39(1):22-6. PubMed ID: 7913877
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.
Gregorian SK; Battisto JR
Cancer Immunol Immunother; 1990; 31(6):325-34. PubMed ID: 2386978
[TBL] [Abstract][Full Text] [Related]
9. Introduction of the interferon gamma gene into mouse T lymphoma cells with low MHC class I-expression results in selective induction of H-2Dk and concomitant enhanced metastasis.
Geldhof AB; VandenDriessche T; Opdenakker G; De Baetselier P
Cancer Immunol Immunother; 1996 Jul; 42(6):329-38. PubMed ID: 8830735
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression in murine renal cell carcinoma. II. Identification of responsible lymphoid cell phenotypes and examination of elimination of suppression.
Gregorian SK; Battisto JR
Cancer Immunol Immunother; 1990; 31(6):335-41. PubMed ID: 1974826
[TBL] [Abstract][Full Text] [Related]
11. Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity.
Chovatiya N; Kaur K; Huerta-Yepez S; Chen PC; Neal A; DiBernardo G; Gumrukcu S; Memarzadeh S; Jewett A
Cancer Immunol Immunother; 2022 Dec; 71(12):2929-2941. PubMed ID: 35507102
[TBL] [Abstract][Full Text] [Related]
12. MHC class Ib-restricted CD8
Li Q; Lin L; Shou P; Liu K; Xue Y; Hu M; Ling W; Huang Y; Du L; Zheng C; Wang X; Zheng F; Zhang T; Wang Y; Shao C; Melino G; Shi Y; Wang Y
Proc Natl Acad Sci U S A; 2023 Oct; 120(43):e2304689120. PubMed ID: 37856544
[TBL] [Abstract][Full Text] [Related]
13. Effect of interferon gamma on the sensitivity of bovine-papilloma-virus(BPV1)-transformed cell lines to cell-mediated cytotoxicity.
Laatikainen A; Schultz-Suhonen L; Mäntyjärvi R
Cancer Immunol Immunother; 1992; 35(3):205-10. PubMed ID: 1322243
[TBL] [Abstract][Full Text] [Related]
14. Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.
Geiger C; Nössner E; Frankenberger B; Falk CS; Pohla H; Schendel DJ
J Mol Med (Berl); 2009 Jun; 87(6):595-612. PubMed ID: 19271159
[TBL] [Abstract][Full Text] [Related]
15. CD8(+) T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway.
Lionello I; Mangia P; Gattinoni L; Pende D; Cippone A; Sensi M; Rigatti P; Traversari C
Cancer Immunol Immunother; 2007 Jul; 56(7):1065-76. PubMed ID: 17195078
[TBL] [Abstract][Full Text] [Related]
16. A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.
Geiger C; Regn S; Weinzierl A; Noessner E; Schendel DJ
J Transl Med; 2005 Jul; 3():29. PubMed ID: 16045799
[TBL] [Abstract][Full Text] [Related]
17. Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.
Frankenberger B; Regn S; Geiger C; Noessner E; Falk CS; Pohla H; Javorovic M; Silberzahn T; Wilde S; Buchner A; Siebels M; Oberneder R; Willimsky G; Pezzutto A; Blankenstein T; Schendel DJ
World J Urol; 2005 Jul; 23(3):166-74. PubMed ID: 15997395
[TBL] [Abstract][Full Text] [Related]
18. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
Falk CS; Noessner E; Weiss EH; Schendel DJ
Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
[TBL] [Abstract][Full Text] [Related]
19. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
